封面
市場調查報告書
商品編碼
1190456

角膜植入物市場——增長、趨勢、COVID-19 的影響和預測 (2023-2028)

Corneal Implant Market - Growth, Trends, and Forecasts (2023 - 2028)

出版日期: | 出版商: Mordor Intelligence | 英文 109 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內,角膜植入物市場的複合年增長率預計為 6.1%。

COVID-19 大流行的迅速出現對全世界的眼科手術產生了重大影響。 由於眼科手術被視為擇期手術,疫情期間擇期手術的暫停減少了全球接受眼科手術的患者數量。 同樣在 2020 年 3 月,作為該國應對 COVID-19 的一部分,CMS 建議停止擇期手術。 此外,在 2020 年 3 月,AAO 公佈了臨床指南,建議眼科醫生停止除緊急和急診醫療以外的醫療。 此外,正如國際環境研究與公共衛生雜誌在 2021 年 8 月宣布的那樣,在放寬大流行限制措施後,沒有看到反彈效應。 雙側同步白內障手術 (SBCS) 佔 2019 年 5 月至 2021 年 3 月進行的白內障手術的 0.77%,而 2021 年 4 月至 2021 年 5 月為 6.5%。 因此,隨著 COVID-19 病例開始消退,在大流行早期影響市場的 COVID-19 大流行已經得到了顯著覆蓋。

市場的增長主要歸功於角膜植入技術的進步、老年人口的增加以及全球眼病發病率的增加等因素。 這些因素導致醫療機構對角膜植入物的大量需求。 老年人口易患 Fuchs 營養不良,可通過內皮角膜移植術 (EK) 進行治療。 根據 2020 年 3 月發表在《視網膜和眼部研究進展》上的一篇論文,晚發性 Fuchs 內皮營養不良在美國很常見,影響了大約 4% 的 40 歲以上人群。 大皰性角膜病變也是接受白內障手術的老年人中最常見的疾病。 對於此類患者,建議進行 EK 手術。 此外,根據聯合國 2022 年世界人口老齡化報告,世界 65 歲及以上人口的比例預計將從 2022 年的 10% 增加到 2050 年的 16%。 到 2050 年,世界 65 歲及以上人口將是 5 歲以下兒童人數的兩倍多,與 12 歲以下兒童人數幾乎持平。 因此,人口老齡化的增加將帶動整體市場的增長。

此外,由於對膠原蛋白人工角膜的生物相容性和低成本進行了評估,因此對膠原人工角膜的需求正在增加,從而導致生物工程人工角膜的發展。 此外,該領域研發活動的增加也促進了市場增長。 例如,2020 年 7 月,CorNeat Vision 開發了一種易於植入且價格低廉的人工角膜 CorNeat KPro。 CorNeat KPro 旨在替換受損、變形或混濁的角膜,有望為沒有角膜的患者提供完整和即時的視力康復。 該產品預計將於 2022 年獲得 CE 標誌和美國 FDA 批准。 同樣在 2021 年 6 月,以色列眼科初創公司 EyeOn Medical 的旗艦產品 EndoArt 獲得了 CE 標誌,這是世界上第一個用於對抗角膜水腫的合成角膜植入物。 通過這種方式,上述技術發展有助於增加對角膜植入物的需求。

此外,全球範圍內眼病發病率的上升也導致了對角膜植入物的大量需求。 角膜植入物用於治療圓錐角膜、角膜混濁、角膜失明和其他眼部疾病。 根據美國角膜研究基金會 2020 年的統計,普通人群中每 10 萬人中就有 50 到 200 人患有圓錐角膜疾病。 由此,預計隨著圓錐角膜疾病患者人數的增加,角膜植入物的需求也會增加。 而根據 RNIB 2020 的統計數據,估計到 2050 年英國將有 410 萬人受到失明的影響。 此外,根據2021年WHO統計,2020年全球將有近視或遠視約22億人,角膜混濁將有420萬人。 如此龐大的數字表明對角膜植入物的需求很高。 因此,上述所有因素目前都在促進角膜植入物市場的增長。

然而,外科手術和眼科設備的高成本以及替代療法的可用性是抑制市場增長的因素之一。

角膜植入物市場趨勢

預計在預測期內角膜穿透率將大幅增長

推動侵入性角膜移植增長的一個主要因素是越來越多的人患有眼外傷和眼部疾病。 穿透性角膜移植術用於治療患有眼部疾病(例如角膜潰瘍和感染性角膜炎)的患者。 此外,穿透性角膜移植術(penetrating keratoplasty,PKP)是治療角膜外翻的首選方法,是治療角膜不耐受和矯正視力患者的標準,光學和視覺效果顯著,已成為一種技術。

此外,穿透性角膜移植手術數量的增加表明對角膜植入物的需求不斷增長。 根據 EBAA 的 2021 年眼庫統計報告,美國分配給角膜移植的供應組織(包括長期儲存組織)總數為 79,641 份,比 2020 年的 66,278 份增加了 20.2%。 2021 年,美國移植了 49,110 個半保留角膜,22,928 個出口到國外。 根據同一份文件,美國的滲透性角膜移植術 (PK) 移植數量為 16,269(增長 5.6%),EK 數量為 30,098,增長 15.3%。 因此,角膜移植手術數量的增加預示著角膜移植需求的增長。 由於這些原因,預計該部門在預測期內將顯著增長。

北美佔全球市場份額最大

在北美地區,美國所佔份額最大,預計在預測期內仍將佔據主導地位。 該地區日益增長的奉獻意識和多個組織的存在是該地區市場增長的一些關鍵驅動力。 例如,EBAA 每年 11 月舉辦眼球捐贈月活動,以提高人們對角膜捐贈和移植的認識。 預計這些努力將增加該國進行的眼科手術的數量。

此外,圓錐角膜患病率的增加預計將增加對角膜植入物的需求,這有望在預測期內推動市場增長。 例如,根據 EBAA 2021 報告,每 2,000 名美國人中就有 1 人患有圓錐角膜。 症狀通常出現在生命早期,在青少年和成人中最為普遍。 這可能會產生對該產品的需求。

此外,根據CDC 2020年6月的統計數據,2020年美國約有1200萬40歲以上的人患有視力障礙。 因此,該地區視力障礙的高發率增加了眼科手術的數量,這進一步導致了對角膜植入物的需求增加。

因此,在預測期內,上述所有因素都有望提振該地區的市場。

角膜植入物市場競爭分析

由於多個區域和全球市場參與者的存在,角膜植入物市場高度分散。 這些參與者專注於增長戰略,例如新產品發布、現有產品創新和併購。 一些市場參與者也專注於為人眼提供角膜,重點是眼球捐贈。 在全球市場上運營的主要參與者包括 CorneaGen、CorNeat Vision、Aurolab、KERAMED Inc. 和 Price Vision Group。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動力
    • 角膜植入技術進展
    • 不斷增長的老年人口
    • 眼病發病率增加
  • 市場製約因素
    • 手術和眼科設備費用高昂
    • 替代療法的可用性
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分(基於價值的市場規模 - 百萬美元)

  • 按植入物類型
    • 人工角膜植入物
    • 人體角膜植入物
  • 通過方法
    • 內皮角膜移植術
    • 經角膜移植術
    • 其他手術類型
  • 疾病適應症
    • 圓錐角膜
    • Fuchs 角膜內皮變性
    • 傳染性角膜炎
    • 角膜潰瘍
    • 其他疾病
  • 最終用戶
    • 醫院
    • 門診手術中心
    • 眼科中心
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 世界其他地區

第六章競爭格局

  • 公司簡介
    • Florida Lions Eye Bank
    • CorNeat Vision
    • CorneaGen
    • San Diego Eye Bank
    • Alabama Eye Bank
    • Aurolab
    • Cornea Biosciences
    • KERAMED INC.
    • Price Vision Group
    • LinkoCare LifeSciences AB
    • Presbia PLC
    • AJL Ophthalmic SA
    • DIOPTEX
    • Massachusetts Eye and Ear

第七章市場機會與未來趨勢

簡介目錄
Product Code: 72190

The corneal implants market is projected to register a CAGR of 6.1% during the forecast period.

The rapid emergence of the COVID-19 pandemic has had a significant impact on ophthalmic surgery across the globe. The suspension of elective procedures during the pandemic reduced the number of patients undergoing ophthalmic surgery globally, as ophthalmic procedures are considered elective procedures. Also, in March 2020, CMS recommended the cancellation of elective surgery as part of the national response to COVID-19. Moreover, in March 2020, the AAO released practice guidelines advising ophthalmologists to cease providing any treatment other than urgent and emergent care. Moreover, as per August 2021 published by the International Journal of Environmental Research and Public Health, no rebound effect was observed once the pandemic restrictions were eased. Simultaneous bilateral cataract surgeries (SBCS) constituted 6.5% of cataract procedures performed in April 2021 and May 2021 compared with 0.77% carried out between May 2019 and March 2021. Hence, the COVID-19 pandemic impacted the market at the initial stages of the pandemic but then started to cover significantly as the COVID-19 cases started to subside.

The market growth can be largely attributed to the factors such as technological advancements in corneal implants, the increasing prevalence of the geriatric population, and growing incidences of eye disorders worldwide. These factors are leading to a huge demand for corneal implants in healthcare facilities. The geriatric population is prone to suffer from Fuchs' dystrophy which is treated with endothelial keratoplasty (EK). According to a March 2020 article published in Progress in Retinal and Eye Research, the late-onset form of Fuchs' endothelial dystrophy is a common condition, affecting approximately 4% of people above 40 years of age in United States. In addition, bullous keratopathy is the most common condition among older people who undergo cataract surgery. Such patients are recommended to undergo an EK procedure. Moreover, as per the World Population Ageing 2022 report by the UN, the share of the global population aged 65 years or above is projected to rise from 10% in 2022 to 16% in 2050. By 2050, the number of persons aged 65 years or over worldwide is projected to be more than twice the number of children under age 5 and about the same as the number of children under age 12. Thus, the increase in the geriatric population will fuel overall market growth.

Moreover, the demand for collagen-based artificial corneas is increasing owing to their biocompatibility and low cost which has led to the development of bio-engineered artificial corneas. In addition, increased R&D activities in this area are contributing to market growth. For instance, in July 2020, CorNeat Vision developed an easily implantable and affordable artificial cornea, CorNeat KPro. The CorNeat KPro has been designed to replace scarred, deformed, or opacified corneas and is anticipated to fully and immediately rehabilitate the vision of corneally blind patients. The product is expected to achieve CE marking and US FDA clearance in 2022. Also, in June 2021, Israeli ophthalmology startup, EyeOn Medical, received a CE Mark for its flagship product EndoArt, the world's first synthetic corneal implant designed to counteract corneal edema. Thus, the aforementioned technological developments are contributing to the rising demand for corneal implants.

Also, due to the growing incidence of eye disorders worldwide, there is a huge demand for corneal implants. Corneal implants are used in the treatment of keratoconus, corneal opacity, corneal blindness, and other eye disorders. As per the 2020 statistics by the Cornea Research Foundation of America, 50 to 200 out of every 100,000 people in the general population were affected by keratoconus disorder in 2020. This indicates that an increase in several people suffering from keratoconus disorder is expected to increase the demand for corneal implants. In addition, as per the 2020 statistics by the RNIB, an estimated number of 4.1 million people in United Kingdom will be affected by blindness by 2050. Furthermore, as per the WHO statistics of 2021, globally, approximately 2.2 billion people had near or distant vision impairment and 4.2 million people had corneal opacities in 2020. Such a huge number indicates a high demand for corneal implants. Thus, all the above-mentioned factors are currently augmenting the growth of the corneal implant market.

However, the high costs of surgical procedures and ophthalmic devices and the availability of alternative treatments are some of the factors impeding the market growth.

Corneal Implants Market Trends

Penetrating Keratoplasty is Expected to Witness a Significant Growth During the Forecast Period

The major factors attributed to the growth of invasive keratoplasty are the increasing number of people suffering from eye-ball injuries and eye disorders. Penetrating keratoplasty procedures are performed to treat patients suffering from eye disorders such as corneal ulcers and infectious keratitis. In addition, penetrating keratoplasty (PKP) is preferred for treating ectatic corneal disease and has been the standard procedure for the treatment of keratoconus patients with remarkable optical and visual outcomes for keratoconus patients that are contact lens intolerant or have corrected visual acuity.

Moreover, an increasing number of penetrating keratoplasty procedures indicates the rising demand for corneal implants. According to the 2021 Eye Banking Statistical Report by the EBAA, the total number of United States-supplied tissue distributed for keratoplasty (including long-term preserved tissue) was 79,641, a 20.2% increase from 66,278 in 2020. 49,110 intermediate-term preserved corneas were transplanted in United States, and 22,928 were exported internationally in 2021. As per the same source, the number of penetrating keratoplasty (PK) grafts in United States was 16,269 (a 5.6% increase), while EK numbers increased by 15.3% to 30,098. Hence, the increasing number of penetrating keratoplasty surgeries indicates the rising demand for corneal implants. Thus, given the above-mentioned factors, the segment is anticipated to grow significantly during the forecast period.

North America Accounted for the Largest Share in the Global Market

Within North America, United States has held the major share of the market and is expected to dominate during the forecast period. The increasing awareness about eye donation in the region and the presence of several organizations are a few of the major factors accounting for the growth of the market in the region. For instance, the EBAA celebrates eye donation month each November to raise awareness about cornea donation and transplantation. Such initiatives are likely to increase the number of eye surgeries performed in the country.

Additionally, the increasing prevalence of keratoconus is expected to increase the demand for corneal implants, which is expected to boost the growth of the market during the forecast period. For instance, according to the EBAA 2021 report, keratoconus affects one in every 2,000 Americans. It generally manifests early in life and is most prevalent among teenagers and adults. This is likely to create demand for the product.

Moreover, as per the June 2020 statistics by the CDC, approximately 12 million people aged 40 years and above suffered from vision impairment in United States in 2020. Thus, the high prevalence of vision impairment in the region has boosted the number of ophthalmic surgeries that further contribute to the rising demand for corneal implants.

Thus, all the aforementioned factors are expected to boost the market in the region during the forecast period.

Corneal Implants Market Competitive Analysis

The corneal implants market is highly fragmented due to the presence of several regional and global market players. These players focus on growth strategies such as new product launches, innovations in existing products, and mergers and acquisitions. Some of the market players are also focusing on the provision of human eye corneas while maintaining a focus on eye donations. Key players operating in the global market are CorneaGen, CorNeat Vision, Aurolab, KERAMED Inc., and Price Vision Group, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Technological Advancements in Corneal Implants
    • 4.2.2 Increasing Prevalence of Geriatric Population
    • 4.2.3 Growing Incidences of Eye Disorders
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Surgical Procedures and Ophthalmic Devices
    • 4.3.2 Availability of Alternative Treatments
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Implant Type
    • 5.1.1 Artificial Corneal Implant
    • 5.1.2 Human Corneal Implant
  • 5.2 By Procedure Type
    • 5.2.1 Endothelial Kertoplasty
    • 5.2.2 Penetrating Keratoplasty
    • 5.2.3 Other Procedure Types
  • 5.3 By Disease Indication
    • 5.3.1 Keratoconus
    • 5.3.2 Fuschs' Dystrophy
    • 5.3.3 Infectious Keratitis
    • 5.3.4 Corneal Ulcers
    • 5.3.5 Other Disease Indications
  • 5.4 By End User
    • 5.4.1 Hospitals
    • 5.4.2 Ambulatory Surgical Centers
    • 5.4.3 Ophthalmic Centers
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Florida Lions Eye Bank
    • 6.1.2 CorNeat Vision
    • 6.1.3 CorneaGen
    • 6.1.4 San Diego Eye Bank
    • 6.1.5 Alabama Eye Bank
    • 6.1.6 Aurolab
    • 6.1.7 Cornea Biosciences
    • 6.1.8 KERAMED INC.
    • 6.1.9 Price Vision Group
    • 6.1.10 LinkoCare LifeSciences AB
    • 6.1.11 Presbia PLC
    • 6.1.12 AJL Ophthalmic SA
    • 6.1.13 DIOPTEX
    • 6.1.14 Massachusetts Eye and Ear

7 MARKET OPPORTUNITIES AND FUTURE TRENDS